LBRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LB

Mkt Cap

$1.19B

Volume

650.09K

Next Earnings

November 5th

Loading chart

LB

LBRXLB Pharmaceuticals Inc Common Stock

LBRX

Pay with—

Available Balance0.00

LB

Mkt Cap

$1.18B

Volume

650.09K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)LB Pharmaceuticals Inc announced equity awards to newly appointed Chief Medical Officer Dr. Susan G. Kozauer and Chief Financial Officer Joseph Miller. Each executive received options to purchase 200,000 shares at an exercise price of $37.22, vesting over 4 years with a 10-year term. The grants were made as inducement awards under Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Oct 9, 2026

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in SchizophreniaLB Pharmaceuticals announced that its Phase 3 NOVA-2 trial of LB-102 for schizophrenia will report topline results in the first half of 2027, ahead of previous guidance. The accelerated timeline reflects faster-than-expected enrollment across 25 U.S. sites. The company maintains sufficient cash runway through Q2 2029 to fund multiple clinical readouts, including Phase 2 trials in bipolar depression and adjunctive MDD.GlobeNewswire Inc. · Jul 22, 2026

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)LB Pharmaceuticals Inc (Nasdaq: LBRX) announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. As an inducement to join the company, Zergebel received an equity award of options to purchase 75,000 shares at an exercise price of $32.95 per share, vesting over 4 years. The company continues advancing its lead candidate LB-102, a novel antipsychotic in Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression.GlobeNewswire Inc. · Jul 10, 2026

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsFive psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.Benzinga · Feb 27, 2026

LB Pharmaceuticals Announces $100.0 Million Private PlacementLB Pharmaceuticals Inc (LBRX) announced a $100 million private placement of common stock and pre-funded warrants at $21.17 per share from institutional investors. The company plans to use proceeds to fund a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder, with closing expected on February 6, 2026.GlobeNewswire Inc. · Feb 5, 2026

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & CultureLB Pharmaceuticals announced the appointments of Ellen Rose as Senior Vice President of Corporate Affairs and Lindsay Beaupre as Senior Vice President of People and Culture. Both executives bring extensive experience from leading biopharmaceutical and financial services companies. The appointments come as the company advances LB-102, its novel benzamide candidate, into Phase 3 trials for schizophrenia and Phase 2 trials for bipolar depression.GlobeNewswire Inc. · Jan 6, 2026

to start trading

LB

LBRXLB Pharmaceuticals Inc Common Stock

LBRX

Pay with—

Available Balance0.00

Your PositionYou don't own any LBRX yet.

Related Tickers

Earnings